SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy. Geographic variation in the incidence of hypertension in pregnancy. Am J Obstet Gynecol 1988;158:803.
  • 2
    The National Institute for Clinical Excellence, The Scottish Executive Health Department, The Department of Health Social Services and Public Safety Northern Ireland. Why Mothers Die 1997–1999: The Fifth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. London: RCOG Press, 2001.
  • 3
    Duley L. Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean. Br J Obstet Gynaecol 1992;99:54753.
  • 4
    Department of Health. Confidential Enquiry into Stillbirths and Deaths in Infancy. London: Department of Health, 1996.
  • 5
    Douglas KA, Redman CW. Eclampsia in the United Kingdom. BMJ 1994;309:1395400.
  • 6
    Duley L, Gulmezoglu AM. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database Syst Rev 2000;CD002960 [DOI: 10.1002/14651858.CD002960].
  • 7
    Duley L, Henderson-Smart D. Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database Syst Rev 2003;CD000128 [DOI: 10.1002/14651858.CD000128].
  • 8
    Duley L, Henderson-Smart D. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst Rev 2003;CD000127 [DOI: 10.1002/14651858.CD000127].
  • 9
    Duley L, Gülmezoglu AM, Henderson-Smart DJ. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev 2003;CD000025 [DOI: 10.1002/14651858.CD000025].
  • 10
    Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: arandomised placebo-controlled trial. Lancet 2002;359:187790.
  • 11
    Nelson KB. Magnesium sulfate and risk of cerebral palsy in very low-birth-weight infants. JAMA 1996;276:18434.
  • 12
    Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics 1995;95:2639.
  • 13
    Schendel DE, Berg CJ, Yeargin-Allsopp M, Boyle CA, Decoufle P. Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. JAMA 1996;276:180510.
  • 14
    Crowther C, Hiller J, Doyle L, Haslam R; for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA 2003;290:266976.
  • 15
    Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev 2002;CD001060 [DOI: 10.1002/14651858.CD001060].
  • 16
    Duley L, Carroli G, Farrell B, Moodley J, Neilson J; on behalf of the Magpie Trial Collaborative Group. The Magpie Trial. Lancet 2002;360:13312.
  • 17
    Magpie Trial Follow Up Study Management Group. The Magpie Trial Follow Up Study: outcome after discharge from hospital for women and children recruited to a trial comparing magnesium sulphate with placebo for pre-eclampsia [ISRCTN86938761]. BMC Pregnancy Childbirth. 2004;4:5.
  • 18
    Magpie Trial Follow Up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for women at 2 years. BJOG DOI: 10.1111/j.1471-0528.2006.01166.x.
  • 19
    Farrell B, Duley L. Doing the undoable: Magpie Trial long-term follow up. Lancet (in press).
  • 20
    Squires J, Potter L, Bricker D. The ASQ User’s Guide for the Ages and Stages Questionnaires: A Parent-Completed, Child Monitoring System, 2nd edn. Baltimore, MD: Paul Brookes Publishing Co, 1999.
  • 21
    Bayley N. Manual for the Bayley Scales of Infant Development, 2nd edn. New York, NY: Psychological Corporation, 1993.
  • 22
    Griffiths R. The Abilities of Babies: A Study in Mental Measurement. Revised reprint. Association for Research in Infant & Child Development, Amersham, UK, 1986.
  • 23
    Jones HP, Guildea ZES, Stewart JH, Cartlidge PHT. The Health Status Questionnaire: achieving concordance with published disability criteria. Arch Dis Child 2002;86:1520.
  • 24
    Frankenburg W, Dodds J, Archer P, Shapiro H, Bresnick B. The Denver II: a major revision and restandardization of the Denver Developmental Screening Test. Pediatrics 1992;89:917.
  • 25
    Lejarraga H, Krupitzky S, Y Colaboradores. Guias para la evaluation del desarrollo en el nino menor de seis anos. Argentina: Nestle, 1996.
  • 26
    Phatak AT, Khurana B. Baroda development screening test for infants. Indian Pediatr 1990;28:317.
  • 27
    WHO. Perinatal Mortality: A Listing of Available Information, 7th edn. WHO/FRH/MSM/96. Geneva, Switzerland: WHO, 1996.
  • 28
    Alberman E, Blatchley N, Botting B, Schuman J, Dunn A. Medical causes on stillbirth certificates in England and Wales: distribution and results of hierarchical classifications tested by the Office for National Statistics. Br J Obstet Gynaecol 1997;104:10439.
  • 29
    Alberman E, Botting B, Blatchley N, Twidell A. A new hierarchical classification of cases of infant deaths in England and Wales. Arch Dis Child 1994;70:4039.
  • 30
    Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev 1996;CD000065 [DOI: 10.1002/14651858.CD000065].